- Home
- ELEV vs IRIX Comparison
ELEV vs IRIX Comparison
Compare ELEV & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- IRIX
- Stock Information
- Founded
- ELEV 2019
- IRIX 1989
- Country
- ELEV United States
- IRIX United States
- Employees
- ELEV N/A
- IRIX N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ELEV Health Care
- IRIX Health Care
- Exchange
- ELEV Nasdaq
- IRIX Nasdaq
- Market Cap
- ELEV 20.0M
- IRIX 16.5M
- IPO Year
- ELEV 2021
- IRIX 1996
- Fundamental
- Price
- ELEV $0.34
- IRIX $1.00
- Analyst Decision
- ELEV Buy
- IRIX Hold
- Analyst Count
- ELEV 6
- IRIX 1
- Target Price
- ELEV $2.94
- IRIX $2.00
- AVG Volume (30 Days)
- ELEV 975.2K
- IRIX 77.4K
- Earning Date
- ELEV 05-23-2025
- IRIX 05-13-2025
- Dividend Yield
- ELEV N/A
- IRIX N/A
- EPS Growth
- ELEV N/A
- IRIX N/A
- EPS
- ELEV N/A
- IRIX N/A
- Revenue
- ELEV N/A
- IRIX $48,669,000.00
- Revenue This Year
- ELEV N/A
- IRIX $9.61
- Revenue Next Year
- ELEV N/A
- IRIX N/A
- P/E Ratio
- ELEV N/A
- IRIX N/A
- Revenue Growth
- ELEV N/A
- IRIX N/A
- 52 Week Low
- ELEV $0.22
- IRIX $0.78
- 52 Week High
- ELEV $4.33
- IRIX $3.25
- Technical
- Relative Strength Index (RSI)
- ELEV 48.18
- IRIX 39.26
- Support Level
- ELEV $0.33
- IRIX $1.14
- Resistance Level
- ELEV $0.37
- IRIX $1.19
- Average True Range (ATR)
- ELEV 0.03
- IRIX 0.07
- MACD
- ELEV 0.00
- IRIX -0.01
- Stochastic Oscillator
- ELEV 25.54
- IRIX 4.90
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.